|
| Tuesday, July 26, 2022 |
|
|
The Global Pharmaceutical Industry is Accelerating; Aptorum Group Has Received Orphan Drug Designation from US FDA for Its SACT-1 |
| The aging of the population is accelerating, pharmaceutical technology is constantly updating, and the development of the global pharmaceutical industry continues to accelerate. The pharmaceutical market is expected to maintain a growing trend. According to Frost & Sullivan, the global pharmaceutical market is expected to reach $1,711.4 billion by 2025. more info >> |
|
| Tuesday, September 29, 2020 |
|
|
Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary, Announces Exclusive In-license from Singapore-based Accelerate Technologies to Co-Develop Molecular Based Rapid Pathogen Diagnostics to Track Pathogenic Genome |
| Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, announced its launch of Aptorum Innovations more info >> |
|
| Tuesday, September 8, 2020 |
|
|
Aptorum Group to Hold Investor Webinar and Present at The Wall Street Investor Forum on September 10 |
| Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company focused on novel therapeutics including the development of next-generation approach therapeutics targeting antimicrobial resistance, today announced President and Executive Director more info >> |
|
|
Aptorum Group Joins the BEAM Alliance To Combat Antimicrobial Resistance |
| Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group"), a biopharmaceutical company focused on novel therapeutics including the development of next-generation therapeutics targeting antimicrobial resistance, today announced it joined the Biotech companies in Europe combating Antimicrobial Resistance Alliance based in Europe (the "BEAM Alliance") as full member. more info >> |
|
| Tuesday, September 1, 2020 |
|
|
Aptorum Group Announces Further Positive Data on ALS-4 against MRSA Wound Infection and MRSA Bacteraemia against Linezolid and Vancomycin Respectively in In Vivo Models |
| Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) ("Aptorum Group"), a biopharmaceutical company focused on novel therapeutics including the development of next-generation approach therapeutics targeting antimicrobial resistance more info >> |
|
|
Aptorum Group Announces Further Positive Data on SACT-1 Against Neuroblastoma and Other Potential Tumor Types |
| Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics including orphan diseases and oncology indications more info >> |
|
|
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2020 |
| Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) ("Aptorum Group"or the "Company"), a biopharmaceutical company focuses on the development of novel therapeutics to address global unmet medical needs, today provided a business update and announced financial results for the six months ended June 30, 2020. more info >> |
|
| Monday, July 27, 2020 |
|
|
Aptorum Group Becomes the First Nasdaq Listed Biopharmaceutical Company Admitted to Trading on Euronext Paris Stock Exchange Under the Ticker Symbol APM |
| Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focusing on the development of novel therapeutics to address global unmet medical needs more info >> |
|
| Monday, March 30, 2020 |
|
|
Aptorum Group Collaborates with Covar Pharmaceuticals to Investigate 3 Repurposed Drug Candidates (SACT-COV19) for Coronavirus Disease 2019 (COVID-19) under Existing Smart-ACT Platform and Acticule Infectious Disease Platform |
| Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics for unmet needs including but not limited to infectious, orphan and metabolic disease areas more info >> |
|
|
Aptorum Group Limited Corporate Update and To Hold Q1 2020 Investor Update Call To Discuss Recent Development and Pipeline Progress |
| Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today provides an update on the Company's operations in light of the recent declaration of the coronavirus outbreak as a pandemic declared by the World Health Organisation on March 11, 2020. more info >> |
|
|
|
